Home > Search Results

Results: 9

Clear

We reviewed the evidence about the effects of eculizumab for treating patients with paroxsymal nocturnal hemoglobinuria.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

OBJECTIVE: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

This review concluded that for haemolytic patients with a history of transfusions, eculizumab was effective in reducing haemolysis and transfusion requirements, reducing anaemia and rate of thrombosis, and improving quality of life. The authors' conclusions appear to follow from the available data, however, it should be noted that this judgement of effectiveness was based on one small RCT and two uncontrolled studies of unclear quality.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Dermatomyositis and polymyositis are long‐term inflammatory muscle diseases, causing muscle weakness and disability. For some reason, the body's immune system turns against its own muscles in an autoimmune response. Corticosteroids are the principal treatment but due to side effects, there is a need for additional treatment with drugs that suppress the immune system (immunosuppressants) or modify it (immunomodulatory therapies) to improve patient outcomes. For this review, an update of a review first published in 2005, we found ten randomised trials available, involving 258 participants.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

We reviewed the evidence for drug treatment other than intravenous immunoglobulin, plasma exchange or corticosteroids for people with Guillain‐Barré syndrome (GBS) .

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Expert-reviewed information summary about the use of hematopoietic cell transplantation in treating childhood cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 31, 2017

The study found that for induction therapy in adult renal transplantation no treatment regimen appeared more effective than another in reducing graft loss or mortality, and, for maintenance therapy, none of the treatment regimens was better for all outcomes or appeared most effective at reducing graft loss. When comparing all treatment regimens only one combination of treatments was cost-effective.

Health Technology Assessment - NIHR Journals Library.

Version: August 2016

The study found that tacrolimus maintenance therapy (with azathioprine) and basiliximab induction (with tacrolimus and azathioprine maintenance therapy) were likely to be cost-effective therapies for children and adolescents undergoing renal transplantation. When all immunosuppressive regimens were simultaneously compared using extrapolated adult data, only basiliximab induction therapy with tacrolimus and azathioprine maintenance therapy was cost-effective.

Health Technology Assessment - NIHR Journals Library.

Version: August 2016

Crohn's disease (CD) is a severe, lifelong disease characterised by inflammation of the gastrointestinal mucosa. The impact on patients and society is high as ill health can be lifelong and can negatively affect patients' quality of life. Costs to the NHS are high, particularly for patients needing hospitalisation. Conventional treatment pathways are complex. More recently, a group of drugs called tumour necrosis factor (TNF) inhibitors (anti-TNF-α agents) have been evaluated for their effectiveness in CD. One of these, infliximab, is currently recommended by the National Institute for Health and Clinical Excellence (NICE; 2002) for patients with severe, active CD where patients are refractory to or intolerant of conventional treatment.

Health Technology Assessment - NIHR Journals Library.

Version: February 2011

Systematic Reviews in PubMed

See all (35)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...